Drug intelligence / Profile preview

gallium-68 citrate

Development stage
Phase 3
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

Gallium-68 citrate is a radiopharmaceutical compound consisting of the positron-emitting radioisotope gallium Ga 68 complexed with citrate. Upon intravenous administration, the weakly chelated gallium ion (Ga3+) dissociates and binds to transferrin in the blood, mimicking iron due to similar chemical properties. The resulting Ga3+-transferrin complex accumulates in tissues with increased transferrin receptor expression, such as sites of infection, inflammation, or tumors. This property enables imaging using positron emission tomography (PET), providing high-resolution functional images for diagnostic purposes. Compared to its predecessor gallium-67, gallium‑68 has a much shorter half-life (about 68 minutes), allowing higher tracer doses and rapid patient discharge post-imaging. Clinical applications include detection and assessment of bone and soft tissue infections (including prosthetic joint infections), inflammatory diseases, and certain cancers such as glioma, hepatocellular carcinoma, prostate cancer, Hodgkin’s disease, lung cancer, non-Hodgkin’s lymphoma, malignant melanoma, and leukemia[1][3][4][5][6][8][10].

Other names
Gallium Ga 68 CitrateGALLIUM GA-68 CITRATEUNII-RD9L8XE13LUNII-RD-9L8XE13LUNII-RD 9L8XE13L
02

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on gallium-68 citrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium-68 citrate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call